A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

Saved in:
Bibliographic Details
Published inBlood Vol. 140; no. Supplement 1; pp. 9084 - 9086
Main Authors Bewersdorf, Jan Philipp, Shallis, Rory Michael, Sharon, Elad, Caldwell, Anne, Wei, Wei, Yacoub, Abdulraheem, Madanat, Yazan F., Zeidner, Joshua F., Altman, Jessica K., Odenike, Olatoyosi, Yerrabothala, Swaroopa, Kovacsovics, Tibor, Podoltsev, Nikolai A., Halene, Stephanie, Little, Richard F., Piekarz, Richard, Gore, Steven D., Kim, Tae Kon, Zeidan, Amer M.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 15.11.2022
Online AccessGet full text

Cover

More Information
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-158626